Premenopausal Osteoporosis

Endocrinology and metabolism clinics of North America, 46(1), 117-133

DOI 10.1016/j.ecl.2016.09.007 PMID 28131128

Abstract

Most premenopausal women with low trauma fracture(s) or low bone mineral density have a secondary cause of osteoporosis or bone loss. Where possible, treatment of the underlying cause should be the focus of management. Premenopausal women with an ongoing cause of bone loss and those who have had, or continue to have, low trauma fractures may require pharmacologic intervention. Clinical trials provide evidence of benefits of bisphosphonates and teriparatide for bone mineral density in several types of premenopausal osteoporosis, but studies are small and do not provide evidence regarding fracture risk reduction.

Topics

premenopausal osteoporosis management, secondary osteoporosis young women, low trauma fracture premenopausal, bone mineral density premenopausal women, bisphosphonates premenopausal osteoporosis, teriparatide young women bone, premenopausal bone loss causes, reproductive hormone bone metabolism, glucocorticoid-induced osteoporosis premenopausal, premenopausal fracture risk assessment

Cite this article

Cohen, A. (2017). Premenopausal osteoporosis. *Endocrinology and metabolism clinics of North America*, *46*(1), 117-133. https://doi.org/10.1016/j.ecl.2016.09.007

Related articles